Literature DB >> 16609904

Remodeling of the vascular channels in retinal angiomatous proliferations treated with intravitreal triamcinolone acetonide and photodynamic therapy.

Ferdinando Bottoni1, Mary Romano, Amedeo Massacesi, Fulvio Bergamini.   

Abstract

BACKGROUND: The objective was to describe the remodeling of the vascular channels in stage II retinal angiomatous proliferation (RAP) treated by intravitreal injections of triamcinolone acetonide (TA) and subsequent photodynamic therapy (PDT).
METHODS: Stage II RAP secondary to age-related macular degeneration was documented by dynamic digital fluorescein and indocyanine green angiography in 3 consecutive patients (3 eyes). All eyes were treated with intravitreal injection of TA (4 mg, 0.1 ml) followed by PDT 5-10 days later.
RESULTS: Indocyanine green angiography (ICGA) revealed a complete remodeling of the vascular structure of the three RAPs after treatment. The feeding retinal artery, which shunted a major part of the blood flow from the original arteriole toward the intraretinal neovascular complex before treatment, regained a normal appearance after treatment. With RAP closure, the blood flow was again directed through the original retinal arteriole, and the connection to the RAP was no longer visible.
CONCLUSIONS: Stage II RAPs are difficult lesions to treat. A real remodeling of the vascular lesion is achieved with the combined use of intravitreal TA and PDT. This finding corroborates the need for randomized clinical trials currently under way to evaluate this combination treatment in wet, age-related macular degeneration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16609904     DOI: 10.1007/s00417-006-0311-9

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  11 in total

1.  A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results.

Authors:  Mark C Gillies; Judy M Simpson; Wei Luo; Philip Penfold; Alex B L Hunyor; William Chua; Paul Mitchell; Frank Billson
Journal:  Arch Ophthalmol       Date:  2003-05

2.  Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation.

Authors:  Ferdinando Bottoni; Amedeo Massacesi; Mario Cigada; Francesco Viola; Ilenia Musicco; Giovanni Staurenghi
Journal:  Arch Ophthalmol       Date:  2005-12

3.  Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model.

Authors:  T A Ciulla; M H Criswell; R P Danis; T E Hill
Journal:  Arch Ophthalmol       Date:  2001-03

Review 4.  Angiostatic steroids. Method of discovery and mechanism of action.

Authors:  J Folkman; D E Ingber
Journal:  Ann Surg       Date:  1987-09       Impact factor: 12.969

5.  Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration.

Authors:  P L Penfold; L Wen; M C Madigan; M C Gillies; N J King; J M Provis
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

6.  Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells.

Authors:  N Bandi; U B Kompella
Journal:  Eur J Pharmacol       Date:  2001-08-10       Impact factor: 4.432

7.  Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells.

Authors:  M Nauck; G Karakiulakis; A P Perruchoud; E Papakonstantinou; M Roth
Journal:  Eur J Pharmacol       Date:  1998-01-12       Impact factor: 4.432

8.  Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells.

Authors:  Yu-sheng Wang; Ulrike Friedrichs; Wolfram Eichler; Stephan Hoffmann; Peter Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-01       Impact factor: 3.117

9.  Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment.

Authors:  Francesco Boscia; Claudio Furino; Luigi Sborgia; Michele Reibaldi; Carlo Sborgia
Journal:  Am J Ophthalmol       Date:  2004-12       Impact factor: 5.258

10.  Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor.

Authors:  Ursula Schmidt-Erfurth; Ursula Schlötzer-Schrehard; Claus Cursiefen; Stephan Michels; Arne Beckendorf; Gottfried O H Naumann
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-10       Impact factor: 4.799

View more
  8 in total

1.  Treatment of recurrent retinal angiomatous proliferation with intravitreal triamcinolone acetonide followed by photodynamic therapy with verteporfin: A retrospective case series.

Authors:  Nicola Cardascia; Claudio Furino; Andrea Ferrara; Francesco Boscia; Giovanni Alessio
Journal:  Curr Ther Res Clin Exp       Date:  2009-06

2.  Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone.

Authors:  Ilse Krebs; Katharina Krepler; Ulrike Stolba; Alexandra Goll; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

3.  The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization.

Authors:  Amedeo L Massacesi; Laura Sacchi; Fulvio Bergamini; Ferdinando Bottoni
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-07-25       Impact factor: 3.117

4.  Intravitreal triamcinolone and laser photocoagulation for retinal angiomatous proliferation.

Authors:  T R Krieglstein; A Kampik; M Ulbig
Journal:  Br J Ophthalmol       Date:  2006-08-02       Impact factor: 4.638

5.  Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation.

Authors:  Sandra Joeres; Florian M A Heussen; Tobias Treziak; Silvia Bopp; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-04-17       Impact factor: 3.117

6.  Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation.

Authors:  Katerina Hufendiek; Karsten Hufendiek; Georgios Panagakis; Horst Helbig; Maria-Andreea Gamulescu
Journal:  Int Ophthalmol       Date:  2012-04-18       Impact factor: 2.031

7.  Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP).

Authors:  Lazaros Konstantinidis; Evangelia Mameletzi; Irmela Mantel; Jean-Antoine Pournaras; Leonidas Zografos; Aude Ambresin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-04-29       Impact factor: 3.117

8.  Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration.

Authors:  Timothy Y Y Lai; Wai-Man Chan; David T Liu; Dennis S Lam
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-09-28       Impact factor: 3.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.